Clinical Trials · NCT02590432

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Name: An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Linaclotide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Forest Laboratories
Enrollment: 828
Start date: Nov 2015
Locations: 79 sites, United States
Primary endpoint: Number of Participants With Positive Treatment-Related Anti-Drug Antibodies (ADA) in Serum

View Linaclotide compound reference